These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25362704)

  • 1. Cardiovascular events in early rheumatoid arthritis--role of tumor necrosis factor inhibition.
    Ljung L
    J Rheumatol; 2014 Nov; 41(11):2094-6. PubMed ID: 25362704
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
    J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 May; 74(5):e34. PubMed ID: 25755140
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular events and survival in rheumatoid arthritis: effects of anti-tumor necrosis factor-alpha treatment.
    Cugno M
    Transl Res; 2011 Jan; 157(1):6-9. PubMed ID: 21146145
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Okamoto H
    N Engl J Med; 2006 Nov; 355(19):2047; author reply 2048. PubMed ID: 17099950
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?
    Boers M
    Ann Rheum Dis; 2015 May; 74(5):e33. PubMed ID: 25714930
    [No Abstract]   [Full Text] [Related]  

  • 9. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular disease in the QUEST-RA study, 10 years later.
    Naranjo A; Ferraz-Amaro I
    Arthritis Res Ther; 2019 Nov; 21(1):242. PubMed ID: 31727147
    [No Abstract]   [Full Text] [Related]  

  • 11. Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: comment on the article by Simard et al.
    Moulis G; Sommet A; Lapeyre-Mestre M
    Arthritis Rheum; 2013 Jun; 65(6):1670-1. PubMed ID: 23508973
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rheumatoid arthritis: a cardiovascular disease?].
    Daïen CI; Fesler P
    Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):111-7. PubMed ID: 21885031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.
    Symmons DP; Silman AJ
    Arthritis Rheum; 2004 Jun; 50(6):1703-6. PubMed ID: 15188344
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoplasms as the leading cause of death among patients with rheumatoid arthritis receiving tumor necrosis factor inhibitors: comment on the article by Simard et al.
    Yazici H; Tascilar K; Yazici Y
    Arthritis Rheum; 2013 Jun; 65(6):1670. PubMed ID: 23508926
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals.
    Buch MH; Marzo-Ortega H; Bingham SJ; Emery P
    Rheumatology (Oxford); 2004 Feb; 43(2):243-4. PubMed ID: 14739466
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply: To PMID 22886739.
    Simard JF; Neovius M; Askling J
    Arthritis Rheum; 2013 Jun; 65(6):1671-2. PubMed ID: 23508884
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis.
    McCarey D; Sturrock RD
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S124-6. PubMed ID: 19822058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative management of patients with rheumatoid arthritis treated with TNF-alpha blocking agents.
    Goupille P; Pham T; Sibilia J; Mariette X
    Semin Arthritis Rheum; 2007 Dec; 37(3):202-3; author reply 203. PubMed ID: 17570470
    [No Abstract]   [Full Text] [Related]  

  • 19. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
    Conaghan PG; Quinn MA; O'Connor P; Wakefield RJ; Karim Z; Emery P
    Arthritis Rheum; 2002 Jul; 46(7):1971-2; author reply 1973. PubMed ID: 12124886
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis.
    Gonzalez-Juanatey C; Llorca J; Garcia-Porrua C; Martin J; Gonzalez-Gay MA
    Arthritis Rheum; 2006 Feb; 55(1):150-3. PubMed ID: 16463428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.